Menu Search
Equities

Merck KGaA

MRKX:GER

Merck KGaA

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (EUR)138.30
  • Today's Change0.20 / 0.14%
  • Shares traded214.14k
  • 1 Year change-15.31%
  • Beta0.6784
Data delayed at least 15 minutes, as of Nov 21 2024 16:35 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in EURIncome statement in EURView more

Year on year Merck KGaA's revenues fell -5.57% from 22.23bn to 20.99bn. This along with an increase in the cost of goods sold expense has contributed to a reduction in net income from 3.33bn to 2.82bn, a -15.07% decrease.
Gross margin58.60%
Net profit margin12.90%
Operating margin16.41%
Return on assets5.41%
Return on equity9.54%
Return on investment6.70%
More ▼

Cash flow in EURView more

In 2023, Merck KGaA increased its cash reserves by 6.90%, or 128.00m. The company earned 3.78bn from its operations for a Cash Flow Margin of 18.03%. In addition the company used 1.89bn on investing activities and also paid 1.73bn in financing cash flows.
Cash flow per share10.42
Price/Cash flow per share13.27
Book value per share65.14
Tangible book value per share10.09
More ▼

Balance sheet in EURView more

Merck KGaA has a Debt to Total Capital ratio of 28.61%, a lower figure than the previous year's 33.81%.
Current ratio1.33
Quick ratio0.9103
Total debt/total equity0.4017
Total debt/total capital0.2861
More ▼

Growth rates in EUR

Year on year, growth in dividends per share remained flat while earnings per share excluding extraordinary items fell by -15.09%. Additionally when measured on a five year annualized basis, dividend per share growth ranked highest relative to its industry peers, while earnings per share growth is above the industry average.
Div yield(5 year avg)1.12%
Div growth rate (5 year)11.97%
Payout ratio (TTM)10.53%
EPS growth(5 years)21.40
EPS (TTM) vs
TTM 1 year ago		-6.81
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.